



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/886,241	(06/21/2001	Susana Salceda	DEX-0209	DEX-0209 5811	
26259	7590	01/18/2005		EXAM	EXAMINER	
LICATLA 66 E. MAIN		ELL P.C.	HARRIS, ALANA M			
MARLTON, NJ 08053				ART UNIT	PAPER NUMBER	
				1642		

DATE MAILED: 01/18/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
Advisory Action	09/886,241	SALCEDA ET AL.	
Advisory Action	Examiner	Art Unit	
	Alana M. Harris, Ph.D.	1642	
The MAILING DATE of this communication appe	ears on the cover sheet with the c	orrespondence add	ress
THE REPLY FILED 12 November 2004 FAILS TO PLACE Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (1 condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.	void abandonment of this applica) a timely filed amendment whicl	ation. A proper reply h places the applica	y to a ition in
PERIOD FOR RE	EPLY [check either a) or b)]		
a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).	Advisory Action, or (2) the date set forth later than SIX MONTHS from the mailing	g date of the final rejection	on.
Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Offictimely filed, may reduce any earned patent term adjustment. See 37 CFR 1.136(a).	of extension and the corresponding amo the shortened statutory period for reply ce later than three months after the mail	unt of the fee. The approriginally set in the final	ropriate extension Office action; or
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFR			
2. The proposed amendment(s) will not be entered be	ecause:		
(a) X they raise new issues that would require further	er consideration and/or search (s	see NOTE below);	
(b) they raise the issue of new matter (see Note b	pelow);		
(c) they are not deemed to place the application in issues for appeal; and/or	n better form for appeal by mate	rially reducing or sir	nplifying the
(d) they present additional claims without canceli	ng a corresponding number of fi	nally rejected claim	s.
NOTE: See Continuation Sheet.	•		
3. Applicant's reply has overcome the following reject	tion(s):		
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	parate, timely filed	amendment
5. The a) affidavit, b) exhibit, or c) request for application in condition for allowance because:		dered but does NO	T place the
6. The affidavit or exhibit will NOT be considered bec raised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were	e newly
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we			and an
The status of the claim(s) is (or will be) as follows:			
Claim(s) allowed:			
Claim(s) objected to:			
Claim(s) rejected: <u>3 and 16</u> .			
Claim(s) withdrawn from consideration:			•
8. The drawing correction filed on is a) app	roved or b) disapproved by t	he Examiner.	
9 Note the attached Information Disclosure Statemen	,		

U.S. Patent and Trademark Office PTOL-303 (Rev. 11-03)

10. Other: ____

Continuation of 2. NOTE: Entrance of the after-final amendments would require an updated search, as well as rejection under 35 USC 112, 1st written descrition. Applicants' suggested claim amendment, "naturally occurring allelic variant" embraces a genus of molecules not sufficiently disclosed or taught in the specification..